Lycia Therapeutics, Inc. (LYCA)
NASDAQ: LYCA · Real-Time Price · USD
26.40
-1.33 (-4.80%)
Oct 30, 2026, 4:00 PM EST - Market closed
Lycia Therapeutics Revenue
Lycia Therapeutics had revenue of $4.44M in the twelve months ending June 30, 2026. In the year 2025, Lycia Therapeutics had annual revenue of $6.74M, down -54.87%. That makes Lycia Therapeutics the 40,381st largest company in the world by revenue and 5,384th in the United States.
Revenue (ttm)
$4.44M
Revenue Growth
-54.87%
P/S Ratio
343.35
Revenue / Employee
$143,065
Employees
31
Market Cap
1.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.74M | -8.20M | -54.87% |
| Dec 31, 2024 | 14.94M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
LYCA News
- 6 days ago - Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 8 days ago - Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere - Barrons
- 10 days ago - Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewsWire
- 12 days ago - Lycia Therapeutics Registration statement: Registration filing - Filings
- 12 days ago - Drug developer Lycia Therapeutics targets $938 million valuation in US IPO - Reuters
- 27 days ago - Lycia Therapeutics files for a $100 million IPO, targeting food allergies and autoimmune diseases - Renaissance Capital
- 27 days ago - Lycia Therapeutics IPO Registration Document (S-1) - SEC
- 27 days ago - Lycia Therapeutics Registration statement: Registration filing - Filings